The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
Kirabo A, Park SO, Majumder A, Gali M, Reinhard MK, Wamsley HL, Zhao ZJ, Cogle CR, Bisht KS, Keserü GM, et al. Neoplasia. 2011 Nov; 13(11):1058-68.